Register Login

Larimar Therapeutics Inc (LRMR)

  • Event
  • Oct. 20, 2022, 12:11 UTC

(85% Positive) Larimar Therapeutics, Inc. (LRMR) Announces Enrollment Update for objectives Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 3, 2025, 9:36 a.m.

    📋 Larimar Therapeutics, Inc. (LRMR) - Clinical Trial Update

    Filing Date: 2022-10-20

    Accepted: 2022-10-20 08:11:10

    Event Type: Clinical Trial Update

    Event Details:

    Larimar Therapeutics Inc (LRMR) Announces Clinical Trial Update Larimar Therapeutics Inc (LRMR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: objectives
    • Diseases/Conditions: future operations
    • Collaboration: Company
      • expected in phenotypically normal heterozygous carriers. Next Steps Initiate in Q4 2022
      • expected in Q4 2022
      • expected in 2H 2023

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Larimar Therapeutics Inc
    • CIK: 0001374690
    • Ticker Symbol: LRMR
    • Period End Date: 2022-10-20
    • Document Type: 8-K

Search

News categories